Form 4: Abeona CCO Reports Stock Transactions

Abeona Therapeutics' Chief Commercial Officer, Madhav Vasanthavada, reported the acquisition of restricted stock and a subsequent sale to cover tax obligations.

Summary

• Madhav Vasanthavada, Chief Commercial Officer of Abeona Therapeutics Inc. (ABEO), acquired 76,621 shares of common stock at a price of $0.00 on January 20, 2026.
• These acquired shares are restricted stock, which will vest in three equal installments: one-third on January 20, 2027, one-third on January 20, 2028, and the final one-third on January 20, 2029.
• On January 22, 2026, Mr. Vasanthavada disposed of 12,610 shares of common stock at a weighted average price of $5.2861 per share.
• The sale of these shares was conducted to cover tax obligations associated with the vesting of restricted stock awards.
• Following these reported transactions, Mr. Vasanthavada's direct beneficial ownership of common stock stands at 318,619 shares.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions involving restricted stock acquisition and a subsequent sale to cover tax obligations, which is a common occurrence and does not inherently indicate positive or negative sentiment regarding the company's performance.

Positives

• The Chief Commercial Officer acquired 76,621 shares of restricted common stock, which aligns management's long-term interests with those of shareholders.

Negatives

• The Chief Commercial Officer disposed of 12,610 shares of common stock, reducing direct beneficial ownership, although this was for tax obligations.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders may view the Chief Commercial Officer's acquisition of restricted stock as a positive sign of management's alignment with long-term company performance.
• The sale of shares to cover tax obligations is a routine event for insiders receiving equity compensation and is unlikely to have a significant impact on the broader shareholder base or market perception.

Next Steps

• The restricted stock acquired on January 20, 2026, will vest in three annual installments on January 20, 2027, January 20, 2028, and January 20, 2029.

Key Dates

Recommendation

This Form 4 details routine insider transactions, including the acquisition of restricted stock and a subsequent sale to cover tax obligations. Such transactions are common and do not provide sufficient new information to warrant a change from a 'hold' recommendation based solely on this filing.

Keywords

ABEONA THERAPEUTICS, ABEO, Form 4, insider transaction, restricted stock, equity compensation, Madhav Vasanthavada, Chief Commercial Officer, stock sale